Revelation Biosciences, Inc. WarrantREVBW
About: Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Employees: 9
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
17% more capital invested
Capital invested by funds: $6.76K [Q4 2024] → $7.89K (+$1.13K) [Q1 2025]
13.16% less ownership
Funds ownership: 22.02% [Q4 2024] → 8.86% (-13.16%) [Q1 2025]
27% less funds holding
Funds holding: 11 [Q4 2024] → 8 (-3) [Q1 2025]
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for REVBW.
Financial journalist opinion
We haven’t received any recent news articles for REVBW.